I am very grateful to the Scottish Cardiac Society for supporting my travel to the EHRA EUOPACE-CARDIOSTIM 2017 congress held in Vienna between the 18th and 21st June 2017. As a final year trainee in cardiac devices, this was an excellent forum highlighting the latest and the best in the field of implantable cardiac devices.
I attended some excellent sessions by world-renowned speakers in the field of cardiac devices. Of particular interest to me were sessions on alternative site ventricular pacing – an area of that bears great potential and is definitely creating a lot of interest amongst electrophysiologists and device experts around the globe. The congress also had very interesting sessions on real world experience on the latest technology in the field of devices – such as subcutaneous ICDs and the leadless pacemaker technology. It was also very educational to watch experts describe their ‘nightmare cases’ of cardiac resynchronisation therapy implants in the cath lab and how they tackled them. Live demo sessions were a great resource to observe and learn new techniques/ equipment available that would be of great value in difficult CRT implants. In addition to all of this, the congress provided a great platform for networking with peers and colleagues.
This travel fund also allowed me to take the extremely challenging EHRA (European Heart Rhythm Association) accreditation exam in cardiac devices that was held on the first day of the congress meeting. I am very pleased to inform the Society that I have successfully passed this exam providing me with Level 1 accreditation in cardiac devices. Finally, I thoroughly enjoyed Vienna and it’s awesome weather!
I thank the Society for their on-going support and hope that I can translate the knowledge gained at this conference into clinical practice.
I am profoundly grateful to Scottish Cardiac Society to support me to attend and present at EuroPCR 2017.
EuroPCR is the official annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the world-leading Course in Interventional Cardiovascular Medicine.
Nearly 11,800 interventional cardiologists, nurses, technicians, scientists and industry innovators from around the world shared the latest developments, research, and best practice in treating cardiovascular conditions, including coronary and valvular heart disease and stroke, with minimally invasive endovascular techniques.
EuroPCR celebrated 40 years of angioplasty this year with an exhibition tracing the major milestones in the pioneering history of interventional cardiology. The first EAPCI fellows course was held in conjunction with EuroPCR with interactive lectures from leaders in the field. Stent-Save a life programme was launched during this conference, which involved meeting of representatives from more than 60 countries to discuss the improvement in access to latest therapies and reduction in mortality and morbidity in patients with STEMI.
I was able to preset my case report during a session on technical aspects of complex left main PCI. The session was well attended by the consultants and registrars from all over the world. I had also been able to attend many simulator sessions to gain new skills in interventional cardiology.
I was able to share my experience with colleagues from all across the world and the live sessions during the conference were a great resource to observe international practice in interventional cardiology and interact with the panel of interventionists and attendees. The sessions on complications during PCI were very useful to learn about management of complicated cases.
The Emily Taylor grant helped me to attend the conference, share knowledge and experience with professionals from around the world and learn new skills in interventional cardiology. I am hopeful that my knowledge and skills will be used for improvement of many lives of patients with cardiac problems in general and ischemic heart disease in particular.
Dr Agha Haider Imran
I am extremely grateful to have received support from the Scottish Cardiac Society for travel to the International Forum on Quality & Safety in Healthcare. This international conference was hosted in London and attracts health care workers from around the world. The forum encourages the sharing of ideas and innovations relating to quality and patient safety.
Keynote speakers included Sir Ranulph Fiennes and Chris Hadfield (Astronaut, Commander Space Station). They shared inspirational insights and experiences. Inspiration and resilience was viewed as vital to their successes and the sessions were delivered with health care professionals/settings in mind.
As well as leadership initiatives the forum highlighted patient-focused clinical care and co-design. Several of the sessions were patient led and included patient innovators. Thought-provoking work relevant to 21st century health care.
In addition the educational aspect the event is a great opportunity to talk to other like minded professionals and on this occasion to display a poster highlighting the improvement work we have been doing in Forth Valley.
The Emily Taylor travel award gave me the opportunity to attend this excellent conference and to share the work we have done with regard to Improving the care of families with Hypertrophic cardiomyopathy.
I am extremely grateful to receive support from the Scottish Cardiac Society for travel to the ‘Midlands-echo,’ Foundation Echocardiography course in Stoke. This is a three day echo course that is pitched at the level of a complete beginner and is promoted by the British Society of Echocardiography. Faculty include cardiology consultants, registrars and senior sonographers. The course was attended by approximately 30 delegates, who ranged from F2 to ST3, but generally all were interested in a career in cardiology. Over the three days the course was run, there are a number of lectures and hands-on echocardiography sessions in small groups. There was the opportunity to scan subjects with normal anatomy as well as those with common heart / valve abnormalities. There were no assessments or exams and so the course felt relaxed and it was a supportive environment. Overall I found this course to be highly useful and it has given me a great deal more confidence with the basics of echocardiography. I hope to use this foundation to begin working towards the accreditation examination of the British Society of Echocardiography. The Emily Taylor travel award gave me the opportunity to attend this excellent course, which will be useful for many years to come.
Dr Michael Freeman
The SCS travel grant allowed me to attend the American College of Cardiology meeting in Washington in March 2017. I presented a poster detailing my research study “Is it safe to use high-sensitivity cardiac troponin T to rule out myocardial infarction at presentation?”
I studied 2577 consecutive patients admitted with suspected ACS who had serial troponin samples taken. 636 patients had an initial concentration <5ng/L at presentation. Only 5 of these patients went on to have a significant rise in their peak sample. 4 out of the 5 patients presented <3 hours of presentation. I was able to demonstrate a negative predictive value of 99.2% for myocardial injury if initial concentration is <5ng/L on presentation thus identifying 25% of patients who may suitable for immediate discharge.
The timing of the meeting was important; the same high-sensitive cardiac troponin T assay used in my study (Roche) has just been approved for use in USA. This is the only high-sensitivity assay to be approved for clinical use in USA so there was some interest in my study. This was a fantastic opportunity to share my work and meet colleagues with an interest in this area. I have had several clinicians contact me since the ACC meeting to enquire about my study and there is a potential collaboration on my next study with a renowned group from Minneapolis who have published widely in the area of cardiac markers.
The conference was informative and enjoyable. I would not have been able to attend if I had not been given this support from SCS.
Cardiology Nurse Consultant
was awarded the Scottish Cardiac Society Autumn Meeting prize after a presentation given in 2016. This award provided funding which I used to attend the American College of Cardiology Congress in Washington DC in March 2017. During this meeting I presented research from my ongoing PhD into the optimal use of cardiac troponin to risk stratify patients with suspected acute coronary syndrome. We also used this meeting as a platform to launch our new clinical app’, detailing the chest pain pathway we developed as part of an ongoing trial of high-sensitivity cardiac troponin implementation across Central Scotland (www.highsteacs.com). Conferences such as ACC provide a unique opportunity for networking, and I was fortunate to meet with other interested research groups in the field.
I am very grateful for the ongoing support of the Scottish Cardiac Society which enabled me to attend this Congress.
Dr Andrew Chapman
BHF Clinical Research Fellow, Cardiology
University of Edinburgh
Between 18-21 February 2017, I attended the Cardiovascular Research Technologies (CRT) 2017 at the Omni Shoreham Hotel in Washington, DC which was made possible by the support I received from the Scottish Cardiac Society Emily Taylor Travel Endowment.
As a final year subspecialty registrar training in percutaneous coronary intervention (PCI), attending CRT 2017 was an excellent opportunity to gain from the first-rate educational programme which included the topics of coronary, valvular and structural, and also peripheral intervention. I had the opportunity to enhance my knowledge by attending many lectures including presentation of new research trial data, but also learn practical interventional skills from hands-on simulations and live cases.
I found particularly interesting and useful the dedicated sessions for complex coronary intervention including left main stem and multivessel PCI, high risk PCI with haemodynamic support and coronary chronic total occlusion intervention. I also took the opportunity to learn about the latest research and device innovations and developments in the field of percutaneous valvular and structural intervention.
In addition to the main meeting, I participated in the pre-meeting Fellows Masters Program which was aimed at teaching Interventional Cardiology fellows fundamentals of complex coronary intervention and transcatheter aortic valve implantation through didactic and case based lectures, and close faculty – fellow interaction via small group case sessions, simulation, and hands-on workshops.
Overall I found the meeting extremely beneficial and would highly recommend it to other Cardiology Registrars training in percutaneous coronary intervention. I returned from the meeting with renewed enthusiasm to apply the knowledge and practical tips I learned in my daily practice and I am very thankful to the Scottish Cardiac Society Emily Taylor Travel Endowment for offering me the support which made it possible for me to attend this conference.
Specialty Registrar in Cardiology
Aberdeen Royal Infirmary
I was awarded the SCS travel award at the 2016 autumn meeting for presenting my work on Tako-tsubo cardiomyopathy as part of my PhD.
The award allowed me to travel to Washington DC in February 2017 to attend the Society of CMR annual congress, where I was able to present my work on MR spectroscopy in TTC for an early career award. Attending the congress not only gave me the opportunity to present to an international audience but allowed me to meet with other researchers in the field of Cardiac MRI and develop contacts for future collaborations.
The congress itself was informative with clinical and case based sessions as well as new and original research.
Attending the clinical and case based sessions has allowed me to apply for Level 1 CMR accreditation and has advanced my knowledge of clinical CMR, the session on MR Physics for medics was especially useful to simplify the important physics concepts that I had been struggling with.
Without the award from the SCS it would have been difficult for me to attend the congress as a clinical research fellow with limited funds available for travel.
Dr Caroline Scally
Cardiology StR and BHF Clinical Research Fellow
The SCS travel award enabled me to attend the Society for Cardiovascular Magnetic Resonance annual congress in Washington, where I was able to present my preclinical work in Manganese-enhanced MRI. The study investigates Manganese-enhanced MRI and conventional Gadolinium contrast agents in a rodent model of myocardial infarction progressing to ischaemic cardiomyopathy. Our objectives were to compare both agents in myocardial infarction, and assess the capability of Manganese-enhanced MRI to detect dysfunctional calcium-handling in ischaemic cardiomyopathy using T1 mapping. We demonstrated Manganese agents as superior to Gadolinium for defining infarct size, and observed altered calcium handling at different time-points in ischaemic cardiomyopathy. This has relevance to future clinical translational studies in pathophysiology of cardiomyopathy.
The conference provided a valuable opportunity to present my work and discuss ideas for future directions with colleagues from other centres internationally, as well as to publicise this emerging field in MRI. In addition, the pre-conference workshop consisted of a valuable series of talks and seminars on CMR physics, orientated to clinicians. Other talks were highly informative on a breadth of preclinical and clinical topics in cardiovascular MRI.
I am very grateful for the support from the Scottish Cardiac Society in enabling me to attend this international meeting.
Clinical Research Fellow, Cardiology
University of Edinburgh
The European Society of Cardiology Acute Cardiovascular Care Association (ACCA) Congress was held in Lisbon, Portugal from the 14th to 17th October 2016. This congress is focused on acute cardiac pathology, and of interest to our research group, there were two sessions on the diagnosis of type 2 myocardial infarction and myocardial injury, chaired by the lead author of the Universal Definition of Myocardial Infarction, Prof Kristian Thygesen (Aarhus, Denmark).
I attended to present results from a cohort study into the long term outcomes of patients with type 2 myocardial infarction or myocardial injury. Whilst these conditions are distinct entities in clinical guidelines, they are poorly understood, and there are no recommendations for the investigation or management of these patients.
We found patients with type 2 myocardial infarction or myocardial injury were at much higher risk of all-cause mortality at five years, and similar risk of future adverse cardiovascular events to those with type 1 myocardial infarction. Interestingly, those with type 2 myocardial infarction or myocardial injury who had underlying coronary artery disease were at significantly increased risk of future adverse outcomes. We have now formally suggested the presence of coronary artery disease be considered in these patients, and are hopeful this will be considered in the next iteration of the Universal Definition of Myocardial Infarction.
Notably, former Scottish Cardiac Society prize winner Dr Anoop Shah (ST5, S.E Scotland) gave a lecture on the appropriate use of cardiac troponin testing in those with suspected acute coronary syndrome. Dr Shah was awarded the ESC ACCA Research Prize in recognition of his presentation and outstanding achievements in this field.
I would recommend the ACCA Congress for any cardiology trainees keen to improve their knowledge of the investigation or management of acute cardiac pathology. This year there were a number of training workshops on specific clinical scenarios, including acute pacemaker/ICD troubleshooting for the general cardiologist. This is also an excellent opportunity to engage with other European researchers, with an evening reception held for trainees, complete with complimentary refreshments, which (perhaps unsurprisingly) was well attended.
The next ACCA Congress is in Milan 2018, with two smaller events planned for 2017. I am grateful to the Scottish Cardiac Society for supporting my attendance at this valuable meeting.
Dr Andrew Chapman
Clinical Research Fellow (Cardiology)
University of Edinburgh